Sarcopenia

View All

Pharma News Astellas, Eisai, Iovance, Biophytis
FDA Grants Priority Review for Zolbetuximab BLA; FDA Traditional Approval for LEQEMBI for Alzheimer’s Disease; Iovance Announces Regulatory and Clinical Updates for TIL Therapy in Advanced NSCLC; Biophytis Seeks FDA Approval to Launch Phase 3 Study of Potential Treatment of Sarcopenia; Orphan Drug Designation to Marker Therapeutics’s MT-401 for AML Treatment; Axsome Therapeutics Initiates Phase 3 Trial of Solriamfetol for ADHD

Astellas Announces FDA Grants Priority Review for Zolbetuximab Biologics License Application Astellas Pharma Inc. announced that the FDA has accepted and granted Priority Review for the company's Biologics Licence Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-target...

Find More

Sarcopenia: “Aging-Associated Strength Loss Condition”

Sarcopenia is an age-related geriatric syndrome which involves the loss of strength of skeletal muscles. The condition leads to impaired mobility, increased disability, more number of falls, as well as loss of physical function. Sarcopenia is observed in both physically inactive and active people, where factors such...

Find More